A Ru(ii)-arene complex with promising anti-Aβ activity

Area of Science:

• Inorganic Chemistry
• Neuroscience
• Medicinal Chemistry

Background:

• Alzheimer's disease (AD) is linked to amyloid-beta (Aβ) peptide aggregation.
• Metal complexes offer a modular approach to targeting Aβ.
• Aβ naturally coordinates with metal ions, influencing its aggregation.

Purpose of the Study:

• To synthesize and evaluate ruthenium(II)-arene complexes for their ability to inhibit Aβ aggregation.
• To investigate the structure-activity relationships of these complexes.
• To assess the biocompatibility and potential therapeutic applications of promising candidates.

Main Methods:

• Synthesis of five ruthenium(II)-arene complexes with 1,10-phenanthroline ligands.
• Assessment of the impact of complexes on Aβ aggregation.
• Investigation of interactions with imidazole and histidine residues.
• Evaluation of biocompatibility in neuronal cell lines.
• Measurement of serum albumin binding affinity.

Main Results:

• One complex, RuPA (4,7-diamino-1,10-phenanthroline ligand), showed the most significant inhibition of Aβ aggregation.
• RuPA interacted with imidazole, suggesting coordination via histidine residues in Aβ.
• RuPA exhibited excellent biocompatibility with neuronal cells.
• RuPA demonstrated lower binding affinity to human serum albumin compared to ibuprofen.

Conclusions:

• The primary amine groups on the phen ligand are crucial for enhancing anti-Aβ activity.
• RuPA is a promising candidate for further development in Alzheimer's disease therapeutics.
• Understanding the structure-activity relationship is key for designing effective metal-based Aβ inhibitors.